Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Spyre Therapeutics (SYRE) over the last 5 years, with Sep 2025 value amounting to $60.4 million.

  • Spyre Therapeutics' Shares Outstanding (Diluted Average) rose 18.72% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 18.72%. This contributed to the annual value of $47.0 million for FY2024, which is 581.85% up from last year.
  • Per Spyre Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $60.4 million for Q3 2025, which was up 0.13% from $60.3 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $82.2 million for Q2 2022, and its period low was $2.6 million during Q4 2021.
  • In the last 3 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) had a median value of $45.3 million in 2024 and averaged $34.5 million.
  • In the last 5 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) tumbled by 95.35% in 2023 and then skyrocketed by 1,085.48% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $2.6 million in 2021, then rose by 28.19% to $3.4 million in 2022, then surged by 104.59% to $6.9 million in 2023, then surged by 581.85% to $47.0 million in 2024, then increased by 18.72% to $60.4 million in 2025.
  • Its last three reported values are $60.4 million in Q3 2025, $60.3 million for Q2 2025, and $60.3 million during Q1 2025.